Beckman Coulter Life Sciences, a Danaher subsidiary and leader in laboratory automation and innovation, announced the launch of the Vi‑CELL BLU 2.0 Viability Analyzer Software. This major upgrade enables laboratories to modernize cell‑viability workflows while preserving data continuity, compliance, and operational confidence.
The platform is designed to help labs tackle complex cell‑analysis challenges and accelerate the shift from research to biomanufacturing.
Built on the trusted Vi‑CELL BLU instrument, the Vi‑CELL BLU 2.0 Viability Analyzer Software delivers superior data comparability, integrity, and system uptime. This allows R&D and manufacturing teams to modernize workflows without disrupting established processes.
Improved cell‑counting algorithms and configurable analysis settings ensure results align with legacy instruments. Coupled with validated software documentation and application guidance, the Vi‑CELL BLU 2.0 Software simplifies equipment transitions and reduces associated complexity.
“The Vi‑CELL BLU 2.0 Viability Analyzer Software was created to help labs modernize cell‑analysis workflows without compromising data integrity or compliance,” said Dave Kremer, Senior Director of Cell Health and Centrifugation at Beckman Coulter Life Sciences. “By aligning results with legacy systems and adding advanced data controls, we enable customers to adopt the upgrade quickly and confidently while minimizing transition risk.”
Additional enhancements include role‑based access controls, electronic signatures, audit trails, and traceability features. These capabilities support regulated workflows, streamline GMP integration, and ensure consistency across projects, users, and sites.
This advancement underscores Beckman Coulter Life Sciences’ dedication to accelerating scientific innovation and delivering more reliable, scalable cell analysis across the biopharma workflow.